Compare Smith & Nephew plc (SNN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs 10X Genomics Inc — how do they compare? Smith & Nephew plc trades at $30.45 (market cap $12.64B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Smith & Nephew plc is far larger — about 2.3× 10X Genomics Inc's market cap, and Smith & Nephew plc pays a 2.57% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SNN | TXG | |
|---|---|---|
Market Cap | $12.64B | $5.48B |
Sector | Health | Health |
52-Week High | $38.70 | $45.80 |
52-Week Low | $28.73 | $11.34 |
Enterprise Value | $15.41B | $5.02B |
Dividend Yield | 2.57% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
